Approaching tumour therapy beyond platinum drugs: status of the art and perspectives of ruthenium drug candidates.
about
Noble metals in oncologyMetal- and Semimetal-Containing Inhibitors of Thioredoxin Reductase as Anticancer AgentsRuthenium metalation of proteins: the X-ray structure of the complex formed between NAMI-A and hen egg white lysozymeTargeting aquaporin function: potent inhibition of aquaglyceroporin-3 by a gold-based compound1H HR-MAS NMR Based Metabolic Profiling of Cells in Response to Treatment with a Hexacationic Ruthenium Metallaprism as Potential Anticancer DrugThe elements of life and medicinesHydrogen bonding and anticancer properties of water-soluble chiral p-cymene Ru(II) compounds with amino-oxime ligandsSynthesis and anticancer activity of carbosilane metallodendrimers based on arene ruthenium(ii) complexesDesign, synthesis and characterisation of new chimeric ruthenium(II)-gold(I) complexes as improved cytotoxic agents.In vitro and in vivo evaluation of water-soluble iminophosphorane ruthenium(II) compounds. A potential chemotherapeutic agent for triple negative breast cancerKinetic and mechanistic studies on reactions of diruthenium(II,III) with biologically relevant reducing agents.Heteroleptic mononuclear compounds of ruthenium(ii): synthesis, structural analyses, in vitro antitumor activity and in vivo toxicity on zebrafish embryos.A Review on Platelet Activating Factor Inhibitors: Could a New Class of Potent Metal-Based Anti-Inflammatory Drugs Induce Anticancer Properties?Cellular and cell-free studies of catalytic DNA cleavage by ruthenium polypyridyl complexes containing redox-active intercalating ligands.Interaction of a ruthenium hexacationic prism with amino acids and biological ligands: ESI mass spectrometry and NMR characterisation of the reaction products.BODIPY-phosphane as a versatile tool for easy access to new metal-based theranostics.Organometallic Titanocene-Gold Compounds as Potential Chemotherapeutics in Renal Cancer. Study of their Protein Kinase Inhibitory Properties.Quantitative bioimaging by LA-ICP-MS: a methodological study on the distribution of Pt and Ru in viscera originating from cisplatin- and KP1339-treated mice.Preclinical combination therapy of the investigational drug NAMI-A(+) with doxorubicin for mammary cancer.Comparison of KP1019 and NAMI-A in tumour-mimetic environments.Application of imaging mass spectrometry approaches to facilitate metal-based anticancer drug research.Bis-picolinamide Ruthenium(III) Dihalide Complexes: Dichloride-to-Diiodide Exchange Generates Single trans Isomers with High Potency and Cancer Cell Selectivity.Luminescent iminophosphorane gold, palladium and platinum complexes as potential anticancer agents.Antimetastatic activity of novel ruthenium (III) pyridine complexes.Potential anticancer heterometallic Fe-Au and Fe-Pd agents: initial mechanistic insights.Combination of ruthenium(II)-arene complex [Ru(η6-p-cymene)Cl2(pta)] (RAPTA-C) and the epidermal growth factor receptor inhibitor erlotinib results in efficient angiostatic and antitumor activity.New bipyridine gold(III) dithiocarbamate-containing complexes exerted a potent anticancer activity against cisplatin-resistant cancer cells independent of p53 statusAntiproliferative effects of ruthenium-based nucleolipidic nanoaggregates in human models of breast cancer in vitro: insights into their mode of action.Targeted therapy vs. DNA-adduct formation-guided design: thoughts about the future of metal-based anticancer drugs.Benzyl-substituted metallocarbene antibiotics and anticancer drugs.Metal complex interactions with DNA.Combination of ICP-MS, capillary electrophoresis, and their hyphenation for probing Ru(III) metallodrug-DNA interactions.Radiosensitisation of human colorectal cancer cells by ruthenium(II) arene anticancer complexes.Synthesis, Characterization, Cytotoxic Activity, and Interactions with CT-DNA and BSA of Cationic Ruthenium(II) Complexes Containing Dppm and Quinoline CarboxylatesDiruthenium(ii,iii) metallodrugs of ibuprofen and naproxen encapsulated in intravenously injectable polymer-lipid nanoparticles exhibit enhanced activity against breast and prostate cancer cells.Insights into the in vitro Anticancer Effects of Diruthenium-1.Tracking antitumor metallodrugs: promising agents with the Ru(II)- and Fe(II)-cyclopentadienyl scaffolds.Heteroleptic arene Ru(II) dipyrrinato complexes: DNA, protein binding and anti-cancer activity against the ACHN cancer cell line.In vitro and in vivo evaluation of organometallic gold(I) derivatives as anticancer agents.Effects of the ruthenium-based drug NAMI-A on the roles played by TGF-β1 in the metastatic process.
P2860
Q26777745-01997DEC-8893-4356-99C5-CA69C919A677Q26800031-83E2CD46-AACC-4F0D-AB15-21644051248CQ27689147-2CC49C75-5A46-4681-8BC0-0A188C0D5D1CQ28483815-54A4E4B2-F755-4A98-8769-C49B9DC7385CQ28547627-A183C8E3-A025-44FC-8A54-59B2F127877FQ28649323-F90DEEAC-33CC-441C-8E25-03B6BE37A027Q28834484-027A5E3B-461C-49B5-8343-817090ACC49DQ30358389-26415B4C-8742-4666-8744-817942512A6BQ30380707-8A2F7131-AFB9-4DDC-9CAF-E0BE40D661E3Q30398565-0977E48C-B7B6-480B-8B61-AB18D4E3FFF1Q30670864-611A72A0-5D70-4F6B-B5CE-FF085519A890Q31143548-67592EB2-7194-4E9F-8A82-F409F7B08527Q33552144-97198930-E8B0-4A97-BB20-53F4E8DF4B97Q33670035-DADDF4E5-1066-4320-A6E1-259B05EFE4E9Q34327703-064CA162-C565-4B57-80E9-0D14E49C342BQ34509157-7254A10F-55E0-4557-83B2-0086DF121880Q34576153-DF162E22-F4D1-4F26-93E8-94C2B1C3D29CQ35167846-A8BC829B-6226-4BD9-A92D-D13B8914C6A7Q35359370-E82825A1-6690-4E83-B35F-441766F0E9BAQ36086603-8ADCEF58-A5EC-4603-BA6B-018FB06C1EDDQ36268494-2E680030-82BE-4FA3-9280-C6FECEEF23E8Q36287265-D4C20F2A-14C1-4912-9731-596AA90FE8FAQ37269801-EFE787E7-1E89-47FE-A2BE-A83CFB4F584DQ37373102-B95C0B71-B5B3-439D-9EAF-F3BF1974299DQ37432620-5A89D9C6-DCE7-4268-8E9B-59EA29FEDA30Q37657640-12FB2ED1-3BCB-4B57-AE87-8E2043620CDBQ37686897-1C10E818-AF1B-4EAD-8929-BD821C0EDB68Q37724010-CA0D2BB5-3029-4169-9AC4-940B03E7CB52Q38011996-43BC4B17-DAC4-47B1-8BA6-AAB6363E21B5Q38207472-C056B5C1-FA75-4651-83F9-DFF86791FEDBQ38271731-554D2A1C-D35A-4F60-9683-B6CDE2C82345Q38289334-ED1C983A-FFD9-43A1-9A8B-36A0638FEB7DQ38381001-ABCB87E7-97BF-4E23-B19A-B798931B8F01Q38621306-098DBF56-6548-4D71-A897-AF9A8DE0FA2EQ38662609-622FEE69-3601-4E5B-90E9-5C78F07EEAEAQ38750151-B99C6339-C847-4A11-B30F-3BED9B6CBFC1Q38776872-9BAC47C7-0738-4918-BA67-B533E0694C58Q38783737-9D371EA3-5E82-442D-BF4C-15CDB033DCBAQ38827745-434561EA-7BA7-4E1F-BB05-98DF35E96FB5Q38835381-96A02C9D-0771-4B21-9FA2-255CFCA78610
P2860
Approaching tumour therapy beyond platinum drugs: status of the art and perspectives of ruthenium drug candidates.
description
2011 nî lūn-bûn
@nan
2011 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Approaching tumour therapy bey ...... of ruthenium drug candidates.
@ast
Approaching tumour therapy bey ...... of ruthenium drug candidates.
@en
Approaching tumour therapy bey ...... of ruthenium drug candidates.
@nl
type
label
Approaching tumour therapy bey ...... of ruthenium drug candidates.
@ast
Approaching tumour therapy bey ...... of ruthenium drug candidates.
@en
Approaching tumour therapy bey ...... of ruthenium drug candidates.
@nl
prefLabel
Approaching tumour therapy bey ...... of ruthenium drug candidates.
@ast
Approaching tumour therapy bey ...... of ruthenium drug candidates.
@en
Approaching tumour therapy bey ...... of ruthenium drug candidates.
@nl
P2093
P1476
Approaching tumour therapy bey ...... of ruthenium drug candidates.
@en
P2093
J H Beijnen
J H M Schellens
P356
10.1016/J.JINORGBIO.2011.09.030
P577
2011-09-29T00:00:00Z